Grifols S.A. Logo

Grifols S.A.

ISIN: ES0171996087 | Ticker: GRF | LEI: 959800HSSNXWRKBK4N60
Sector: Health CareSub-Industry: Pharmaceuticals
Country: Spain

About Grifols S.A.

Company Description

Grifols, with presence in more than 100 countries, is a global pharmaceutical company specializing in the Hemotherapy sector, the medical discipline that treats disease using blood components.

Year founded

1940

Served area

Worldwide

Headcount

23,000

Headquarters

Cl Jesus y Maria 6, 8022 Barcelona – Spain

Financial statements

Download as Excel
Line item in (eur) 01.01.2019 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A N/A 15,274,776,000.00 19,233,835,000.00 21,533,977,000.00
Noncurrent Assets N/A N/A 12,109,822,000.00 13,723,555,000.00 16,880,390,000.00
Property Plant And Equipment N/A N/A 2,324,107,000.00 2,547,497,000.00 3,270,937,000.00
Goodwill N/A N/A 5,332,271,000.00 6,228,901,000.00 7,011,909,000.00
Intangible Assets Other Than Goodwill N/A N/A 1,557,650,000.00 1,636,950,000.00 2,949,147,000.00
Investment Accounted For Using Equity Method N/A N/A 1,869,020,000.00 1,999,776,000.00 1,955,177,000.00
Deferred Tax Assets N/A N/A 149,921,000.00 152,507,000.00 174,923,000.00
Noncurrent Financial Assets At Amortised Cost N/A N/A 195,149,000.00 358,161,000.00 582,175,000.00
Current Assets N/A N/A 3,164,954,000.00 5,510,280,000.00 4,653,587,000.00
Inventories N/A N/A 2,002,281,000.00 2,259,354,000.00 3,201,357,000.00
Trade And Other Current Receivables N/A N/A 520,158,000.00 499,708,000.00 738,651,000.00
Current Trade Receivables N/A N/A 383,233,000.00 432,197,000.00 608,688,000.00
Other Current Receivables N/A N/A 72,360,000.00 55,063,000.00 73,181,000.00
Current Tax Assets Current N/A N/A 64,565,000.00 12,448,000.00 56,782,000.00
Current Financial Assets At Amortised Cost N/A N/A 11,118,000.00 2,026,469,000.00 31,034,000.00
Cash and cash equivalents 1,033,792,000.00 741,982,000.00 579,647,000.00 2,675,611,000.00 547,979,000.00
Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners N/A N/A N/A 0.00 4,969,000.00
Other Current Assets N/A N/A 51,750,000.00 64,079,000.00 81,814,000.00
Equity And Liabilities N/A N/A 15,274,776,000.00 19,233,835,000.00 21,533,977,000.00
Equity 4,696,604,000.00 6,845,768,000.00 6,720,055,000.00 7,317,098,000.00 8,457,544,000.00
Issued Capital N/A N/A 119,604,000.00 119,604,000.00 119,604,000.00
Share Premium N/A N/A 910,728,000.00 910,728,000.00 910,728,000.00
Treasury Shares N/A N/A 43,734,000.00 164,189,000.00 162,220,000.00
Equity Attributable To Owners Of Parent N/A N/A 5,108,392,000.00 5,523,609,000.00 6,129,938,000.00
Noncontrolling Interests N/A N/A 1,611,663,000.00 1,793,489,000.00 2,327,606,000.00
Liabilities N/A N/A 8,554,721,000.00 11,916,737,000.00 13,076,433,000.00
Noncurrent Liabilities N/A N/A 7,219,583,000.00 8,442,425,000.00 11,120,586,000.00
Noncurrent Provisions N/A N/A 27,271,000.00 24,122,000.00 110,063,000.00
Noncurrent Government Grants N/A N/A 17,008,000.00 15,036,000.00 15,123,000.00
Deferred Tax Liabilities N/A N/A 556,813,000.00 633,984,000.00 1,034,823,000.00
Other Noncurrent Liabilities N/A N/A 16,391,000.00 333,000.00 15,000.00
Current Liabilities N/A N/A 1,335,138,000.00 3,474,312,000.00 1,955,847,000.00
Current Provisions N/A N/A 11,175,000.00 31,407,000.00 56,339,000.00
Trade And Other Current Payables N/A N/A 746,189,000.00 785,342,000.00 862,335,000.00
Trade And Other Current Payables To Trade Suppliers N/A N/A 601,618,000.00 628,992,000.00 731,918,000.00
Other Current Payables N/A N/A 141,089,000.00 151,834,000.00 114,730,000.00
Current Tax Liabilities Current N/A N/A 3,482,000.00 4,516,000.00 15,687,000.00
Other Current Liabilities N/A N/A 153,162,000.00 219,272,000.00 241,487,000.00
Line item in (eur) 01.01.2019/
01.01.2020
01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 5,098,691,000.00 5,340,038,000.00 4,933,118,000.00 6,063,967,000.00
Other Income 0.00 0.00 16,302,000.00 22,235,000.00
Profit Loss From Operating Activities 1,131,365,000.00 996,132,000.00 595,064,000.00 805,680,000.00
Finance Income 114,197,000.00 8,021,000.00 11,551,000.00 33,859,000.00
Finance Costs 342,965,000.00 249,639,000.00 277,994,000.00 496,524,000.00
Profit Loss Before Tax 817,103,000.00 878,629,000.00 350,453,000.00 361,257,000.00
Income Tax Expense Continuing Operations 168,459,000.00 169,639,000.00 85,126,000.00 90,111,000.00
Profit Loss From Continuing Operations 648,644,000.00 708,990,000.00 265,327,000.00 271,146,000.00
Profit (loss) 648,644,000.00 708,990,000.00 265,327,000.00 271,146,000.00
Profit Loss Attributable To Owners Of Parent 625,146,000.00 618,546,000.00 188,726,000.00 208,279,000.00
Profit Loss Attributable To Noncontrolling Interests 23,498,000.00 90,444,000.00 76,601,000.00 62,867,000.00
Line item in (eur) 01.01.2019 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A 648,644,000.00 708,990,000.00 265,327,000.00 271,146,000.00
Adjustments For Reconcile Profit Loss N/A 569,960,000.00 409,766,000.00 574,493,000.00 780,436,000.00
Adjustments For Decrease Increase In Inventories N/A 323,748,000.00 -164,631,000.00 157,474,000.00 600,245,000.00
Adjustments For Depreciation And Amortisation Expense N/A 302,455,000.00 321,533,000.00 359,767,000.00 407,864,000.00
Other Adjustments For Noncash Items N/A 605,000.00 16,427,000.00 -25,398,000.00 -22,270,000.00
Other Adjustments To Reconcile Profit Loss N/A 267,505,000.00 88,233,000.00 214,726,000.00 372,572,000.00
Adjustments For Reconcile Profit Loss N/A 569,960,000.00 409,766,000.00 574,493,000.00 780,436,000.00
Interest Paid Classified As Operating Activities N/A 236,179,000.00 155,788,000.00 155,120,000.00 350,387,000.00
Interest Received Classified As Operating Activities N/A 9,487,000.00 3,773,000.00 407,000.00 4,054,000.00
Income Taxes Paid Refund Classified As Operating Activities N/A 107,797,000.00 131,510,000.00 30,595,000.00 196,436,000.00
Other Inflows Outflows Of Cash Classified As Operating Activities N/A -336,593,000.00 -284,342,000.00 -187,063,000.00 -543,341,000.00
Cash Flows From Used In Operating Activities N/A 568,933,000.00 1,110,336,000.00 596,975,000.00 -10,867,000.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities N/A 2,708,000.00 272,000.00 639,000.00 3,284,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 310,383,000.00 280,154,000.00 247,373,000.00 266,491,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 101,922,000.00 82,406,000.00 67,715,000.00 109,069,000.00
Cash Flows From Used In Investing Activities N/A -548,789,000.00 -858,115,000.00 -854,149,000.00 -1,978,823,000.00
Payments To Acquire Or Redeem Entitys Shares N/A 0.00 0.00 125,703,000.00 3,459,000.00
Proceeds From Borrowings Classified As Financing Activities N/A 120,079,000.00 108,541,000.00 3,324,399,000.00 1,134,168,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 53,809,000.00 272,877,000.00 495,327,000.00 1,207,253,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 73,785,000.00 79,037,000.00 82,692,000.00 104,287,000.00
Dividends Paid Classified As Financing Activities N/A 238,740,000.00 113,230,000.00 258,946,000.00 592,000.00
Other Inflows Outflows Of Cash Classified As Financing Activities N/A -90,552,000.00 -7,953,000.00 -75,500,000.00 -2,787,000.00
Cash Flows From Used In Financing Activities N/A -332,356,000.00 -354,401,000.00 2,297,679,000.00 -173,493,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A 20,402,000.00 -60,155,000.00 55,459,000.00 35,551,000.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A -291,810,000.00 -162,335,000.00 2,095,964,000.00 -2,127,632,000.00
Cash and cash equivalents 1,033,792,000.00 741,982,000.00 579,647,000.00 2,675,611,000.00 547,979,000.00

Please note that some sums might not add up.

Filings & Publications

Insider Trades

Sign up and we will give you access!

Capital markets information

ISIN

ES0171996087

LEI

959800HSSNXWRKBK4N60

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Bolsa de Madrid

Stock Index

IBEX35

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.